Join the 'Vyvanse' group to help and get support from people like you. How it works
Vyvanse Blog
| Tweet |
Another Drug 'Take-Back Day' Scheduled for Saturday
Posted 26 Apr 2012 by Drugs.com
THURSDAY, April 26 – The fourth National Prescription Drug Take-Back Day is scheduled for Saturday from 10 a.m. to 2 p.m., the U.S. Drug Enforcement Administration says. The event gives Americans an opportunity to safely dispose of unwanted and unused prescription drugs. At the third Take-Back Day last October, participants turned in more than 377,000 pounds (188.5 tons) of unwanted or expired medications at more than 5,300 sites located in all 50 states. In total, the three Take-Back Days have taken in nearly 1 million pounds of prescription drugs during the past 13 months. "The amount of prescription drugs turned in by the American public during the past three Take-Back Day events speaks volumes about the need to develop a convenient way to rid homes of unwanted or expired prescription drugs," DEA administrator Michele Leonhart said in an agency news release. "The DEA remains hard at ... Read more
Related support groups: Suboxone, Xanax, Methadone, Oxycodone, Percocet, OxyContin, Hydrocodone, Vicodin, Adderall, Morphine, Norco, Fentanyl, Klonopin, Lortab, Subutex
Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
Posted 8 Feb 2012 by Drugs.com
PHILADELPHIA, February 7, 2012 /PRNewswire/ – Vyvanse (lisdexamfetamine dimesylate), an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the first medication both proven to work and approved for maintenance treatment in adults with ADHD. Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults (aged 18 to 55 years) who were receiving treatment with Vyvanse for a minimum of 6 months prior to enrolling in the study. Significantly more patients treated with Vyvanse maintained ADHD symptom control compared with ... Read more
Related support groups: Attention Deficit Hyperactivity Disorder (ADHD), Vyvanse, Lisdexamfetamine
Prescriptions for Stimulants, Painkillers Soaring Among Youth
Posted 30 Nov 2010 by Drugs.com
TUESDAY, Nov. 30 – The number of prescriptions for controlled medications such as opioids and stimulants has nearly doubled in adolescents and young adults since 1994. The trend, reported in the December issue of Pediatrics, mirrors a similar increase in misuse of these drugs, with adolescents and young adults' illicit use of prescription drugs now outstripping all other illicit drug use except marijuana. The researchers couldn't attribute the increased misuse directly to more prescriptions, but did urge both physicians and patients to be vigilant when considering the use of drugs such as Oxycontin or Ritalin. "Our study did not look at the relationship between prescribing and misuse, but the increased prescribing increases the potential availability [of these drugs]," said study author Dr. Robert Fortuna, an assistant professor of internal medicine and pediatrics at the University of ... Read more
Related support groups: Suboxone, Methadone, Oxycodone, Percocet, OxyContin, Hydrocodone, Vicodin, Adderall, Morphine, Norco, Fentanyl, Lortab, Subutex, Opana, Phentermine
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
Posted 15 Nov 2010 by Drugs.com
PHILADELPHIA - November 15, 2010 Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD.1 Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.1 This adolescent indication for Vyvanse is good news for kids in this age group diagnosed with ADHD and their caregivers as it offers an additional treatment option to help them manage their symptoms, said Mike Yasick, Senior Vice President of Shire's ADHD Business. The approval of Vyvanse for children and adults - and now ... Read more
Related support groups: Vyvanse, ADHD, Lisdexamfetamine
FDA Medwatch Alert: Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder - Communication about an Ongoing Safety Review
Posted 15 Jun 2009 by Drugs.com
Products involved include: Focalin, Focalin XR (dexmethylphenidate HCl ); Dexedrine, Dexedrine Spansules, Dextroamphetamine ER, Dextrostat (dextroamphetamine sulfate); Vyvanse (lisdexamfetamine dimesylate); Desoxyn (methamphetamine); Concerta, Daytrana, Metadate CD, Metadate ER, Methylin, Methylin ER, Ritalin, Ritalin-LA, Ritalin-SR (methylphenidate); Adderall, Adderall XR (mixed salts amphetamine); Cylert (pemoline) and generics.FDA notified healthcare professionals that it is providing its perspective on study data published in the American Journal of Psychiatry on the potential risks of stimulant medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children. This study, funded by the FDA and the National Institute of Mental Health (NIMH), compared the use of stimulant medications in 564 healthy children from across the United States who died suddenly to the ... Read more
Related support groups: Attention Deficit Hyperactivity Disorder (ADHD), Adderall, Vyvanse, Concerta, Focalin, Dexedrine, Desoxyn, Cylert